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Abstract
The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016 resulted in 
intense efforts to evaluate the efficacy of several specific countermeasures developed through years 
of preclinical work, including the first clinical trials for therapeutics and vaccines. In this Review, 
we discuss how the experience and data generated from that outbreak have helped to advance the 
understanding of the use of these countermeasures for post-exposure prophylaxis against Ebola 
virus infection. In future outbreaks, post-exposure prophylaxis could play an important part in 
reducing community transmission of Ebola virus by providing more immediate protection than 
does immunisation as well as providing additional protection for health-care workers who are 
inadvertently exposed over the course of their work. We propose provisional guidance for use of 
post-exposure prophylaxis in Ebola virus disease and identify the priorities for future preparedness 
and further research.
Introduction
The 2013–16 Ebola virus disease epidemic in west Africa evolved rapidly from a small 
outbreak in Guinea into an unprecedented global public health emergency. By the time the 
WHO-declared public health emergency of international concern ended in March, 2016, 28 
646 cases and 11 323 deaths had been reported, mainly in Guinea, Sierra Leone, and Liberia.
1
 Infection of household contacts of individuals with Ebola virus disease and exposure in the 
context of traditional burial practices were major factors in the transmission of Zaire 
ebolavirus in the west Africa outbreak.2,3 The most effective strategies for primary 
prevention of person-to-person transmission are probably early identification of individuals 
who have contracted the infection and isolation of these individuals in suitable health-care 
facilities, as well as community-based infection prevention and control practices. Effective 
post-exposure prophylaxis could augment traditional public health measures to reduce 
community transmission of Ebola virus. A closely related concept was recently explored in a 
ring vaccination cluster-randomised trial4 involving administration of the recombinant 
vesicular stomatitis virus-vectored vaccine expressing the Ebola virus surface glycoprotein 
(rVSV-ZEBOV) to both contacts of individuals with Ebola virus disease and contacts of 
contacts. Complete protection was induced by the vaccine (ie, it had 100% efficacy) in that 
no new cases of the disease occurred from 10 days onwards after vaccination, which was the 
predefined primary outcome for the study. However, on days 0–9, incident cases occurred in 
vaccine recipients at a similar rate to that of controls. This finding indicates that post-
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exposure prophylaxis interventions that provide immediate protection might be needed to 
augment the delayed protection induced by the vaccine.
Another tragic consequence of the west Africa epidemic was infection of almost 900 health-
care workers, which resulted in more than 500 deaths and depleted an already limited health-
care resource.5 The devastating effects on the health-care infrastructure and numbers of 
health-care workers will reverberate for years to come in the three principally affected 
countries. Health-care workers have been infected in virtually every outbreak of Ebola virus 
disease, and often the clustering of infection or deaths of health-care workers has signalled 
the onset of an outbreak.6,7 The most effective protection for health-care workers is the 
implementation of a safe system of work, including environmental and administrative 
controls and appropriate personal protective equipment to limit exposure to infectious 
patients and body fluids during clinical care.8–11 Outbreaks of Ebola virus disease have 
largely occurred in remote and resource-limited locations where safe systems of work have 
been inadequate, especially early in outbreaks, resulting in numerous exposures, infections, 
and deaths.6,7,12 Even when sophisticated safe systems of work are in place, accidental 
exposures to Ebola virus occur over the course of caring for patients,13,14 and less 
commonly in laboratory workers handling clinical samples or doing filovirus research.15–17 
If the exposure is recognised—for example, a splash or sharps injury—then effective post-
exposure prophylaxis could prove to be life-saving. Future outbreaks of Ebola virus disease 
are inevitable, and all options for protection of health-care workers must be evaluated.
Preclinical work on filovirus-specific countermeasures has been ongoing for many years, 
and the first therapeutic and vaccine clinical trials were done during the 2013–16 west 
Africa outbreak of Ebola virus disease.4,18–22 Additionally, a small number of case reports 
exist of monitored experimental use of therapeutics for treatment of this disease, and use of 
both antivirals and vaccines for post-exposure prophylaxis.16,23–27 We review the relevant 
preclinical and clinical data, and propose a clinical algorithm for use of post-exposure 
prophylaxis in Ebola virus disease on the basis of current evidence.
Vaccines
Human Ebola virus disease has a median incubation period of 9–10 days, and infection leads 
to specific immune responses that have been detected in survivors.28–31 Therefore, active 
immunisation during the incubation period could plausibly stimulate protective immune 
responses and prevent or attenuate clinical disease. The vaccine most advanced in 
development is replication-competent rVSV-ZEBOV. Its efficacy as pre-exposure 
prophylaxis has been demonstrated in non-human primate models, in which it is possible to 
achieve 100% protection before lethal challenge with Ebola virus.32 However, experiments 
in very small numbers of non-human primates suggest that the protective efficacy is time 
dependent: complete protection of non-human primates was achieved when the Ebola virus 
challenge was given 7 days after vaccination, but not all animals were protected when the 
virus challenge was given 3 days after vaccination.33 The likely explanation is a delay in the 
generation of a protective immune response.34 If vaccine administration is delayed in non-
human primates until only 20–30 min after lethal challenge, which is perhaps more 
representative of post-exposure prophylaxis, then protective efficacy was 50% in one study.
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 However, active immunisation might have greater efficacy as post-exposure prophylaxis 
in human beings than in non-human primates because the non-human primate model differs 
from human Ebola virus disease in two important respects: the onset of clinical illness is 
faster, and it is uniformly lethal.
Development of the rVSV-ZEBOV vaccine offered the first opportunity for use of post-
exposure prophylaxis in Ebola virus disease in human beings. A single use of rVSV-ZEBOV 
as post-exposure prophylaxis, following a laboratory needlestick injury, was reported before 
the recent west Africa outbreak.16 A further seven individuals—health-care workers with 
varied potential exposures to Ebola virus over the course of their work in west Africa—who 
received rVSV-ZEBOV as post-exposure prophylaxis have been reported.23,26,27 None of 
these individuals developed Ebola virus infection, but all of the reports were uncontrolled, 
and thus whether immunisation prevented disease remains unknown. In all but one of these 
cases, rVSV-ZEBOV was administered at a high dose of 1 × 108 plaque-forming units, and 
all recipients developed adverse effects following administration of the vaccine. Most 
developed transient feverishness, which is particularly problematic when managing patients 
who have had potential exposure to Ebola virus. In phase 1/2, placebo-controlled, double-
blinded randomised trials,18,36,37 including more than 200 participants in total, the rVSV-
ZEBOV vaccine demonstrated dose-related reactogenicity and immunogenicity at doses 
ranging from 3 × 105 to 5 × 107 plaque-forming units. The expedited development of the 
rVSV-ZEBOV vaccine during the west Africa outbreak culminated in a cluster-randomised 
ring vaccination study,4 in which a lower dose of vaccine (2 × 107 plaque-forming units) 
than that reported in the uncontrolled cases of post-exposure prophylaxis23,26,27 was used. 
This dose of vaccine was generally well tolerated and had a very high efficacy in prevention 
of onset of Ebola virus disease from 10 days after vaccination, as noted previously.4 
However, the vaccine did not seem to provide early protection against Ebola virus disease in 
individuals in whom the virus is presumably already incubating. As a result of the trial 
design, the effectiveness reported largely reflects pre-exposure prophylaxis, and the 
contribution of post-exposure prophylaxis, if any, is not possible to discern.
Studies of the kinetics of immune responses after vaccination also highlight the likely delay 
in development of protective responses. In phase 1/2 studies18,36,37 of rVSV-ZEBOV, none 
of the human volunteers had detectable antibodies against Ebola virus glycoprotein on day 7 
post-immunisation, even at the highest doses of vaccine; 90–95% of vaccine recipients had 
detectable antibodies by day 14, and all had detectable virus-specific IgG by day 28. 
However, uncertainty exists regarding which antibody types and what blood levels of 
antibody correlate with protection against infection or disease. A weak protective effect 
could even be attributable to antigen non-specific activation of innate immunity by a 
replicating virus-vectored vaccine.38 No new cases of Ebola virus disease were diagnosed in 
the ring vaccination study4 from 10 days post-vaccination, which suggests that meaningful 
protective immunity probably develops in human beings within this time. When considering 
active immunisation for post-exposure prophylaxis, these data need to be set against the 
incubation period of Ebola virus in human beings, which is on average 9 days and probably 
shorter after percutaneous exposure.3 Taken together, these findings suggest that vaccine-
induced immunity is insufficiently rapid to reliably prevent Ebola virus disease in human 
beings when administered as post-exposure prophylaxis, even if the vaccine were given as 
Fischer et al. Page 4
Lancet Infect Dis. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
quickly as possible following exposure. Whether it might still attenuate clinical disease is 
unknown. Additionally, current vaccines are specific for Zaire ebolavirus and might offer 
less or no protection against other Ebola virus species.
Several other vaccines for Ebola virus disease are in development, but no published animal 
or clinical data exist on their use as post-exposure prophylaxis. Unlike rVSV-ZEBOV, most 
are virus-vectored but non-replicating vaccines, which are generally used in heterologous, 
prime-boost immunisation regimens that could prove to be highly effective for pre-exposure 
prophylaxis.39–53 However, they might be less well suited to the demands of post-exposure 
prophylaxis and the need to induce a protective immune response as rapidly as possible.
Passive immunotherapy
Humoral immune responses have been associated with survival from Ebola virus disease,
33,54,55
 and passive immunotherapy has been considered for both treatment and post-
exposure prophylaxis. Initial efforts focused on polyclonal antibody preparations such as 
hyperimmune goat and equine serum.25,56,57 Convalescent blood products, including whole 
blood and plasma from survivors of Ebola virus disease, have been administered to patients 
in Africa and to patients who were medically evacuated to the USA and Europe, but the 
benefits of this treatment are unclear.20,58–68 In at least one patient, the use of convalescent 
plasma was associated with acute respiratory distress syndrome that was attributed to 
transfusion-related acute lung injury.62 Results from one uncontrolled non-randomised 
Ebola virus disease treatment trial20 suggest that transfusion of 500 mL of convalescent 
plasma with unknown levels of antibodies was not associated with a significant 
improvement in survival in patients with Ebola virus disease compared with historical 
controls, which is consistent with non-human primate data suggesting that convalescent 
serum is ineffective for treatment.69 The total amounts of Ebola virus IgG antibodies 
administered in convalescent plasma were measured subsequently, and higher doses were 
associated with a lower viral load after infusion but with no significant association with 
mortality.67 The use of convalescent plasma for post-exposure prophylaxis has not been 
reported. Hyperimmune globulin was shown to reduce mortality when administration was 
started 2 days after Ebola virus challenge in non-human primates,70 but production of 
hyperimmune globulin against Ebola virus from convalescent plasma for human use has not 
been reported.
Preparations of specific monoclonal antibodies have become an area of interest. Far greater 
concentrations of specific antibody can be achieved reliably using monoclonal antibody 
preparations than with unconcentrated convalescent plasma.66 These preparations have 
demonstrated remarkable efficacy in early treatment of non-human primates with clinically 
apparent disease. An optimised cocktail of three human–mouse chimeric monoclonal 
antibodies directed against the Ebola virus glycoprotein, known as ZMapp, demonstrated 
100% protection when treatment was delayed until 3, 4, or even 5 days after administration 
of a lethal dose of Ebola virus.71 This approach is not strictly post-exposure prophylaxis, but 
treatment of disease is widely assumed to be more challenging than post-exposure 
prophylaxis, and therefore its potential efficacy as post-exposure prophylaxis can probably 
be extrapolated from, although not precisely defined by, these models. During the west 
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Africa outbreak, various preparations of three monoclonal antibody combinations (ZMapp, 
ZMab, and MIL77) were used for treatment of Ebola virus disease in the USA and Europe,
60,61,64–66,72–74
 but no conclusions can be drawn about their efficacy from this uncontrolled 
experimental use. A randomised controlled trial21 of ZMapp therapy for Ebola virus disease 
at the end of the outbreak was unable to recruit the planned sample size and suggested, but 
did not definitively establish, benefit in reducing mortality. Two individuals evacuated to the 
UK following very high-risk exposures to Ebola virus (penetrating sharps injuries with 
freshly used hollow bore needles) received monoclonal antibody therapy for post-exposure 
prophylaxis, in both cases starting on day 2 post-exposure.24 Both individuals also received 
the antiviral agent favipiravir. These individuals did not develop laboratory or clinical 
evidence of Ebola virus infection, but whether infection was prevented by post-exposure 
prophylaxis was not possible to determine. Administration of monoclonal antibody 
preparations is generally safe, although a single report exists of anaphylaxis in an individual 
who was rechallenged with monoclonal antibody after many months during treatment of 
recrudescent Ebola virus infection.72 Taken together, the data suggest that specific 
monoclonal antibody preparations are a promising therapeutic for both treatment of and 
post-exposure prophylaxis for Ebola virus disease. However, they are relatively expensive 
and difficult to administer; additionally, current monoclonal antibodies are not broadly 
cross-reactive across Ebola virus species and therefore might not work in future outbreaks, 
although efforts are ongoing to isolate widely cross-reactive monoclonal antibodies, 
including from human survivors of Ebola virus disease.75–79
Small-molecule antiviral agents
Minimally symptomatic Ebola virus infection has been reported, as evidenced by 
seropositivity in contacts who did not themselves develop overt clinical disease.80–86 A 
reasonable assumption is that viral replication occurred in these individuals but was 
naturally controlled to a subclinical threshold. In theory, treatment with a small-molecule 
antiviral agent during the incubation period following exposure to Ebola virus might inhibit 
virus replication sufficiently to prevent or attenuate clinical disease. However, sparse 
experimental and observational data exist to support this strategy, and the time window for 
effective post-exposure prophylaxis using antiviral small molecules has not been defined.
Favipiravir was developed and licensed in Japan for treatment of novel influenza A virus 
infections. It has demonstrated modest but broad antiviral activity against RNA viruses 
through inhibition of viral RNA-dependent RNA polymerases.87 In mouse models of Ebola 
virus disease, high-dose favipiravir can rescue animals following a lethal dose of Ebola virus 
when initiated as late as 6 days after viral challenge.88,89 The dose used is approximately ten 
times higher than that needed for protection in mouse models of lethal influenza. Data for 
the efficacy of favipiravir against Ebola virus disease in non-human primates have not been 
published, but preliminary reports indicate that antiviral effects are dose related (Bavari S, 
US Army Medical Research Institute of Infectious Diseases, personal communication). On 
the basis of human safety data from phase 3 trials for treatment of influenza and availability 
at the time, favipiravir was evaluated in a non-comparative clinical trial19 in the treatment of 
Ebola virus disease in west Africa using a dose regimen that is approximately 50% higher 
than that used in the influenza studies.90 Compared with historical control data, no 
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significant safety signal and no clear survival benefit from treatment were found at this dose, 
although the trial was not designed to prove efficacy. Subsequent pharmacokinetic analysis 
has shown that the dose regimen used, which had been derived from modelling studies, was 
too low to achieve reliable therapeutic drug levels for inhibition of Ebola virus replication.91
Taken together, the data suggest that favipiravir has relatively weak antiviral activity against 
Ebola virus. However, this conclusion does not necessarily preclude efficacy of the drug as 
post-exposure prophylaxis, considering that viraemia in the very early stages of infection, 
when the drug would be administered, would be very low. Favipiravir has been used as post-
exposure prophylaxis in at least five health-care workers with percutaneous accidents and 
suspected Ebola virus exposures during the west Africa outbreak. The dose chosen was the 
same as that used in the west Africa treatment trial,19 although whether this dose is sufficient 
is unclear. In a UK case series, four individuals received post-exposure prophylaxis with 
favipiravir, and two of these individuals with the highest-risk exposures (penetrating sharps 
injuries with freshly used hollow bore needles) received monoclonal antibody therapy in 
addition to the antiviral.24 Similarly, a nurse was evacuated to Switzerland after a moderate 
to high-risk exposure involving the penetration of two pairs of gloves by sharp plastic from 
disposed waste containing infectious biological fluids, and received favipiravir as post-
exposure prophylaxis (Kaiser L, Geneva University Hospitals, personal communication). 
None of these individuals developed laboratory or clinical evidence of Ebola virus infection, 
but whether any infections were prevented by the use of post-exposure prophylaxis is not 
possible to determine from this small number of uncontrolled cases.
Development of potent small-molecule antiviral agents against Ebola virus is a priority for 
treatment of Ebola virus disease. Towards the end of the west Africa outbreak, data were 
published showing complete protection of non-human primates following lethal Ebola virus 
challenge by treatment with GS-5734, an experimental nucleotide analogue that is 
approximately 1000 times more potent in vitro against Ebola virus than is favipiravir.92 This 
study was the first to show a robust therapeutic effect for a small-molecule inhibitor against 
Ebola virus, even when administration was delayed until 3 days after lethal virus challenge. 
Whether the observed efficacy of GS-5734 in animal models of Ebola virus infection will 
translate into clinical efficacy in human beings is currently unknown. To date, only two 
patients with Ebola virus infection have been treated with GS-5734: a British nurse who 
developed recrudescent disease, including CNS infection, 10 months after initial infection;73 
and an infant born to a mother who was infected with the virus.93 Both patients survived, 
and no serious adverse effects were reported. Phase 2 clinical development of GS-5734 for 
Ebola virus disease is ongoing. Further development of this drug might increase its potential 
for post-exposure prophylaxis in the future, especially since it has shown broad and potent 
antiviral activity across filoviruses in vitro.94
Other small-molecule inhibitors of Ebola virus are under development, including the 
nucleoside analogue BCX4430, which has demonstrated broad antifilovirus activity.95 
Treatment of non-human primates 48 h after lethal Ebola virus challenge was found to be 
capable of reducing viral load and significantly delaying, but not preventing, death; at a 
higher dose and starting within an hour of virus challenge, non-human primates were 
completely protected from death.96 Initial phase 1 studies of BCX4430 have been done, and 
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further studies in human beings are planned.96 To date, BCX4430 has not been used for 
treatment or post-exposure prophylaxis of Ebola virus disease.
Other investigational therapeutics from the west Africa outbreak
Before the west Africa epidemic, lipid nanoparticle formulations of small interfering RNAs 
were under development as treatment for Ebola virus disease. The formulation TKM-100802
—when administration was initiated 30 min after lethal virus challenge—demonstrated 
efficacy in protection of non-human primates.97 Its development was placed on partial 
clinical hold after concerns arose about a cytokine release syndrome in the phase 1 study in 
healthy volunteers98 but, early in the west Africa outbreak, TKM-100802 was administered 
to five patients with Ebola virus disease who had been medically evacuated to the USA and 
given once for post-exposure prophylaxis.27,60,61 The efficacy or safety of this therapy is not 
possible to determine from these few uncontrolled uses. One potential advantage of small 
interfering RNA technology is that it can be rapidly adapted to match the outbreak strain of 
Ebola virus: a new formulation, TKM-130803, was specifically engineered for the variant 
responsible for the west Africa epidemic. TKM-130803 was shown to protect non-human 
primates even when administration was delayed until 3 days after lethal virus challenge;99 
however, in a single-arm phase 2 trial,98 it did not demonstrate survival benefit in individuals 
with Ebola virus disease compared with historical controls. Further development of TKM-
Ebola formulations is not currently anticipated, and their use for post-exposure prophylaxis 
is not considered further in this Review.
During the west Africa crisis, repurposed drugs with possible benefit in Ebola virus disease 
also generated considerable interest. Although some repurposed drugs were administered as 
part of treatment of Ebola virus disease, published data are not available to evaluate the 
efficacy or support the use of any particular compound. Careful observation at one Ebola 
treatment centre determined that malaria treatment (for possible concomitant infection) that 
included amodiaquine, which inhibits Ebola virus replication in vitro, might be associated 
with improved survival from Ebola virus disease.100 This hypothesis-generating 
observational study needs to be investigated further in non-human primate models before 
being considered for a formal clinical trial.
Recommendations for post-exposure prophylaxis
Medical countermeasures with potential effectiveness as post-exposure prophylaxis were not 
accessible for the most part before the recent west Africa outbreak of Ebola virus disease. 
Despite the unprecedented scale of the outbreak, very few individuals received post-
exposure prophylaxis and no trial of this strategy was undertaken. Therefore, there are 
insufficient data to inform an evidence-based approach to post-exposure prophylaxis for 
Ebola virus disease. Generation of such data is an obvious research need, and plans to 
address this need should be formulated in advance of the next outbreak so that they can be 
implemented expeditiously. Ideally, any use of post-exposure prophylaxis for Ebola virus 
disease in the future should be part of clinical research, even if only as part of a systematic 
observational study, to build up the relevant evidence base. Inclusion of serial tests in study 
participants for both PCR and serology might provide evidence of exposure to the virus. The 
Fischer et al. Page 8
Lancet Infect Dis. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
following recommendations are intended to stimulate development of studies or trials and 
provide guidance for emergency use outside any study protocol. They are based on first 
principles and the limited evidence reviewed in this article, and follow from an informal 
workshop on post-exposure prophylaxis for Ebola virus disease convened by WHO in 
Bethesda (MD, USA) in June, 2015. The recommendations address two main questions: 
what potential exposures to Ebola virus warrant consideration of post-exposure prophylaxis; 
and which medical countermeasures should currently be considered for post-exposure 
prophylaxis. The recommendations are consensus opinion from the authors and not graded 
because of insufficient high-quality evidence.
What exposure to Ebola virus warrants consideration of post-exposure 
prophylaxis?
Ebola virus disease has a substantial case-fatality rate even with optimal supportive 
treatment, which weighs heavily into the risk–benefit deliberations for administration of 
experimental agents. By contrast, the risk of developing Ebola virus disease following a 
particular type of exposure to the virus is poorly defined, making the risk–benefit assessment 
of experimental therapies for post-exposure prophylaxis more challenging. The key evidence 
about human-to-human transmission of Ebola virus has recently been reviewed,3 and 
provides a framework for consideration of which potential exposures to the virus justify use 
of post-exposure prophylaxis. It is not possible to codify every particular event that might 
lead to potential exposure to the virus, but it is possible to divide exposures into broad 
categories of transmission risk, as shown in table 1. Following categorisation, we infer the 
potential benefit of post-exposure prophylaxis in different situations (table 1) on the basis of 
the following assumptions about any experimental medical countermeasures used: they have 
demonstrated relevant antiviral activity in animal models at least, at doses that are achievable 
in human beings; have safety data in human beings that support their use in healthy 
individuals; and can be administered safely and within a timeframe that is likely to be 
effective for post-exposure prophylaxis. Future evidence could permit further refinements to 
the assessment of transmission risk based on, for example, the viral load of the source. The 
categories are very broad and do not fully reflect the detailed risk assessment that is required 
for each potential exposure. For example, individuals who fall into the intermediate risk 
group because of intact skin exposure might be upgraded to high risk if the exposure was not 
recognised immediately and there was the possibility of subsequent contamination of 
mucous membranes, such as by rubbing their own eyes. After any recognised exposure, first-
aid measures should be followed as soon as possible, such as skin decontamination and 
wound cleaning as appropriate. Optimal first-aid measures are not defined and their benefit 
is unknown, but the use of disinfectants such as chlorine for wound decontamination was 
widespread during the west Africa outbreak.
One special circumstance that might warrant consideration of post-exposure prophylaxis is 
sexual contact and exposure to semen from male survivors of Ebola virus disease. The virus 
can be recovered from semen for many months after survival from Ebola virus disease, and 
male-to-female sexual transmission has now been documented.101–103 The absolute risk and 
upper time limit for sexual transmission of Ebola virus are not known, and post-exposure 
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prophylaxis has not been used in this context to our knowledge. We also propose that 
modelling and studies of post-exposure prophylaxis as an adjunct to ring vaccination should 
be explored to optimise community control of future outbreaks of Ebola virus disease.
Which medical countermeasures should be considered for post-exposure 
prophylaxis?
Characteristics of an ideal agent for post-exposure prophylaxis are listed in the panel. None 
of the currently available countermeasures fulfils these criteria, and there are insufficient 
data to compare these agents directly. Nevertheless, several rational options for post-
exposure prophylaxis can be considered, including passive immunotherapy with monoclonal 
antibodies (eg, ZMapp, which is specific to Zaire ebolavirus) and antiviral agents (such as 
favipiravir and GS-5734, which are probably more broadly active against Ebola virus 
species), and choices should be made according to the particular circumstances (and 
preferably as part of a study). Table 2 summarises the characteristics of leading 
investigational post-exposure prophylaxis countermeasures for Ebola virus disease. 
Accumulating evidence suggests that active immunisation alone with rVSV-ZEBOV might 
not induce protective immunity sufficiently rapidly to provide optimal post-exposure 
prophylaxis. However, immunisation with rVSV-ZEBOV vaccine and chemoprophylaxis 
might not be mutually exclusive options and could be used together to provide both rapid 
and prolonged protection. To pursue this approach, further studies would be required to 
ensure that the antiviral agent used does not inhibit vaccine replication and attenuate the 
immune response; favipiravir, for example, has antiviral activity against rabies virus, a 
rhabdovirus related to vesicular stomatitis virus.104 Similarly, passive immunoprophylaxis 
with monoclonal antibodies directed against the Ebola virus glycoprotein that is expressed in 
the rVSV-ZEBOV vaccine would be expected to interfere with its replication and attenuate 
its immunogenicity, and therefore concurrent administration of rVSV-ZEBOV vaccine and 
monoclonal antibodies against the Ebola virus glycoprotein is not recommended. 
Availability of and access to many of these therapeutics were limiting factors during the 
west Africa outbreak. On the basis of first principles, it makes sense to administer the 
countermeasure as soon as possible after exposure, although the time window for maximum 
effectiveness for each agent is unknown. Particularly for active immunisation and passive 
immunotherapy, it would be important to know that the measures were effective against the 
current circulating species of Ebola virus.
Conclusion
Preparedness for the next outbreak of Ebola virus disease should include a strategy for post-
exposure prophylaxis. Further evidence is needed to better define who should receive post-
exposure prophylaxis and which agents should be used, and therefore studies should be 
developed that can be implemented quickly in future outbreaks. Study design is challenging, 
but at least systematic observational data should be collected on use of post-exposure 
prophylaxis. Predefinition of an agreed minimum dataset would enable data to be aggregated 
from different sites. Initial evidence suggests that pre-exposure vaccination, if available, 
could play a fundamental part in the protection of health-care workers in an outbreak. Post-
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exposure prophylaxis should also be provided in emergencies but, although potentially 
important both to individuals and to enhance confidence among health-care workers, most 
exposures to Ebola virus might not be recognised at the time, limiting its overall 
effectiveness in this context. The potential for post-exposure prophylaxis to prevent 
secondary cases—for example, within a household—warrants further modelling and trials. 
This approach could be an important adjunct to ring vaccination, which appears to be 
effective in prevention of further new infections but might not induce immunity sufficiently 
rapidly to prevent Ebola virus disease in individuals who have already been infected. Care 
will need to be taken to ensure that the approach to post-exposure prophylaxis does not 
interfere with the replication and hence effectiveness of the live-attenuated vaccine. 
Development of vaccines and immunotherapeutics that are broadly active against multiple 
species of Ebola virus remains a high medical priority. Access to many of the vaccines and 
therapeutics discussed in this Review, all of which are currently considered to be 
experimental, remains a substantial obstacle. Plans for a supply pipeline in advance of an 
outbreak, together with standard protocols for use and data collection, would assure both 
access for those in need and the systematic gathering of evidence needed to further refine the 
guidance presented here.
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Panel: Characteristics of an ideal agent for post-exposure prophylaxis 
against Ebola virus disease
• Proven efficacy, preferably in human beings but at least in non-human 
primates
• Rapid onset of protection and efficacy for longest possible time window after 
exposure to Ebola virus
• Broad activity against different Ebola virus species
• Well tolerated, with no serious adverse effects
• Easily administered, preferably orally
• Stable and can be stored and transported easily
• Inexpensive and readily available
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Search strategy and selection criteria
We searched PubMed for the term “Ebola virus” in the title or abstract for manuscripts 
published between Jan 1, 2013, and May 31, 2017. We included selected publications in 
English that provided recent information on Ebola virus with regard to transmission 
during an outbreak, natural history of disease, management of clinical cases, potential 
antiviral therapies and vaccines, immunological responses, and animal models. 
Additionally, we reviewed relevant articles cited in those references and included them as 
primary sources where appropriate.
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